GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,513.00p
   
  • Change Today:
      1.00p
  • 52 Week High: 1,671.00
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,096.39m
  • Volume: 7,336,765
  • Market Cap: £61,978m
  • RiskGrade: 129

GSK, Spero UTI drug trial ends early after meeting target

By Frank Prenesti

Date: Wednesday 28 May 2025

LONDON (ShareCast) - (Sharecast News) - UK pharma giant GSK and its partner Spero Therapeutics on Wednesday said it had ended a late-stage trial of an experimental drug for complicated urinary tract infections early after it met its main target.
The decision comes after a recommendation from an independent committee that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial.

Both firms said the oral drug, known as tebipenem Hbr, was found to be equal to an existing intravenous treatment in hospitalised adult patients.

GSK said it planned to work with US regulatory authorities to include the data as part of a filing in the second half of the year.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,513.00p
Change Today 1.00p
% Change 0.07 %
52 Week High 1,671.00
52 Week Low 1,264.00
Volume 7,336,765
Shares Issued 4,096.39m
Market Cap £61,978m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
56.09% below the market average56.09% below the market average56.09% below the market average56.09% below the market average56.09% below the market average
39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average
Price Trend
36.06% above the market average36.06% above the market average36.06% above the market average36.06% above the market average36.06% above the market average
55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average
Income
69.95% above the market average69.95% above the market average69.95% above the market average69.95% above the market average69.95% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
35.95% below the market average35.95% below the market average35.95% below the market average35.95% below the market average35.95% below the market average
44.83% below the sector average44.83% below the sector average44.83% below the sector average44.83% below the sector average44.83% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 06-Jun-2025

Time Volume / Share Price
16:13 0 @ 1,511.00p
16:13 0 @ 1,511.00p
15:24 0 @ 1,514.50p
16:47 54,842 @ 1,510.99p
14:53 0 @ 1,513.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page